Evaluation and Analysis of Comparative Effectivness of Telmisartan and Olmisartan in Essential Hypertension in Indian Population

Hypertension is one of the most common worldwide diseases afflicting humans and is a major risk factor for stroke, myocardial infarction, vascular disease, and chronic kidney disease. Despite extensive research over the past several decades the etiology of most cases of adult hypertension is still unknown, and control of BP due to the associated morbidity and mortality and cost society, preventing and treating hypertension is an important public health challenge.

The total number of patients included in the study were 155 divided intoGroup A(Olmisartan) were 76Group ‘B’ (Telmisartan) were 79. The sex ratio in group ‘A’, 57% were males and 43% were females;In group ‘B’ 54% were males and 46% were females. All group were comparable. The age distribution was comparable among groups. Most of the patients were in the range of 41–50 years. Mean age in group ‘A’ 45.82 ± 8.11 and 45.70 ± 8.02 in group ‘B’. The ARBs, Olmisartan and Telmisartan are effective in reduction of systolic blood pressure and the anti-hypertensive effects is noted upto 16 weeks of the initiation of treatment problely beyond. The ARBs Olmisartan and Telmisartan are effective in reduction of diastolic blood pressure and the anti-hypertensive effects is noted upto 16 weeks of the initiation of treatment and problely beyond. In both groups ‘A’ and ‘B’, females showed better reduction in systolic and diastolic blood pressure. In both group ‘A’(Olmisartan), and group ‘B’(Telmisartan) patients demonstrated improvement in renal parameters especially serum creatinine. In both Telmisartan and Olmisartan, patients showed minimal side effects and both were well tolerated.